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INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer worldwide, with an estimated 1.4 million
new cases and almost 700,000 related deaths globally each year (1). In Australia, CRC is the second
most commonly reported cancer and second most common cause of cancer-related death (2).
Moreover, Australia has the fourth highest incidence of CRC for men and fifth highest for women
internationally (3, 4). Incidence rates of CRC have at least doubled in many countries since the mid1970s (5–7), although trends vary across countries with stabilizing or declining rates in more recent
years reported in Western Europe and the United States (US), respectively. This trend is reversed
for high-income nations that have recently made the transition from low-income economies (8, 9).
In the majority of cases, CRC develops from non-malignant precursor adenomatous colonic
polyps (adenomas) (10), with the overall adenoma burden dependent on the number, size, villosity, dysplasia grade, and location of adenomas in the colon. Importantly, the average interval
from adenoma appearance to development of CRC is >10 years (11), and the removal of adenomas
reduces CRC incidence and mortality (12, 13). This affords an excellent opportunity for early detection through screening and regular colonoscopic surveillance, and the condition meets the World
Health Organization criteria for diseases suited to screening (14). Patients with prior adenoma are
therefore recommended to undergo regular surveillance colonoscopy (15). Increased surveillance, in
addition to advances in surgical and adjuvant therapy (16), has been shown to reduce CRC incidence
and increase median 5-year survival for CRC from 55.0% in the early 1980s to 65.3% by 2005 (16).
Lifetime prevalence of adenoma is 40–50% (17), however, the majority of adenomas never
develop into malignant neoplasms and only 4–5% of the population eventually develop CRC (18).
Consequently, simply identifying the presence of adenomas does not represent the most efficient
approach for making informed recommendations for the need and timing of follow-up colonoscopic
surveillance and the overall adenoma burden and specific adenoma characteristics should be factored into clinical decision making (12, 13).

USE OF COLONOSCOPY FOR CRC DETECTION
Although some population-based screening programs exist employing fecal occult blood testing
(FOBT), colonoscopy remains the “gold-standard” for detection of CRC and precursor adenomas
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(19). However, others have suggested that colonoscopy is overused
as a primary screening and surveillance tool leading to sizable
increases in the rates of colonoscopy in many countries (20–22).
In Australia, rising usage of colonoscopy has been seen for
over two decades, with Medicare claims for the procedure
increasing by 250% in the last 10 years (23). This increase has
occurred simultaneously with increased capacity within the private hospital sector (24). Given the current trajectory, and when
considered with population aging and the promotion of earlier
screening, it is estimated that over 1 million colonoscopies will
be performed annually by 2020 in Australia (population 24 million) (25). Similar relative trends have been reported elsewhere,
with greater absolute increases, in countries such as the US (26).
Such demand is not sustainable for most health systems, both
in terms of provider capacity and health-care costs, estimated to
be in the multiple billions of dollars annually in western nations
(27). Furthermore, if projected increases in demand are realized,
access to this service will be compromised, especially in public
health systems. Already in Australia waiting times for colonoscopy exceeding 250 days are not uncommon (28, 29).

factors including proximal or distal adenoma location, and the
total adenoma burden over time are often overlooked as risk
factors for future CRC.

INCORPORATING DATA FROM MULTIPLE
PRIOR COLONOSCOPIES
The cumulative burden of prior colorectal adenoma has almost
exclusively been omitted from risk stratification approaches for
surveillance colonoscopy, often due to unavailability of data.
Most research in this area has only incorporated data from the
most recent colonoscopy. However, it is likely that the risk of
adenoma recurrence or development of CRC is modified by
prior adenoma and/or changes in adenoma characteristics over
time. Therefore, risk increases are likely conditional on adenoma
characteristics from multiple earlier examinations rather than
just the most recent investigation.
To date, there has been little published work which has considered longitudinal colonoscopy history for risk prediction of
CRC. Estimates from a relatively small study (n < 3,000) of Dutch
patients investigated predictive ability of baseline colonoscopy on
adenoma burden for up to two subsequent colonoscopies (37).
The authors reported that optimizing timing of colonoscopy
surveillance by incorporating multiple risk factors could result
in 20% fewer surveillance colonoscopies being required annually, while maintaining the same level of effectiveness in terms of
cancer detection and life-years gained (37). Three other studies
have reported on rates of advanced adenoma or CRC incorporating up to two surveillance colonoscopies (38–40), although, as
commented by the US Multi-Society Task Force on Colorectal
Cancer (41), all have important limitations possibly resulting in
selection bias. Despite these weaknesses, findings were consistent
across these studies suggesting that accounting for longitudinal
colonoscopy history could provide important information for
CRC risk prediction. While these results are encouraging, there
is currently a complete lack of findings in the literature beyond
the second surveillance colonoscopy. Consequently, the extent to
which adenoma burden over a patient’s life mediates future CRC
risk is largely unknown.
Due to the lack of empirical data in this area, recommended
intervals for follow-up colonoscopy in most national clinical
guidelines, such as those in the US, UK, Australia, and Europe
(15, 41–43), are almost exclusively based on results of the latest
examination alone. Consequently, existing international guidelines are arguably a compromise that may not accurately define
optimal intervals for repeat surveillance in patients with detected
adenomas over multiple prior colonoscopies.
In Australia, clinical guidelines advocate that a risk assessment
combining the results at baseline and at least one repeat surveillance examination may be a superior tool for CRC prediction than
reliance on findings at the latest examination (15). However, there
is no guidance provided on how to use that information other
than a general statement that endoscopists should be encouraged
to consider previous colonoscopy findings. The authors of the
Australian Clinical Guidelines for Colonoscopy Surveillance
recognize this limitation and recommend further research to

RISK STRATIFICATION APPROACHES
TO CRC DETECTION AND PREVENTION
Researchers, including our team, have previously called for greater
consideration of personalized risk stratification approaches to
primary screening for CRC (30); however, less consideration has
been given to the potential benefits of such approaches for ongoing surveillance. Targeting colonoscopy to patients who stand to
benefit most (i.e., those at higher risk of CRC) through robust
risk stratification would reduce the burden of colonoscopies
to both patients and the health system, while maintaining the
preventive benefits of surveillance colonoscopy. Such targeting
could reduce burden for lower-risk patients, who are less likely
to benefit and reduce waiting times for high-risk patients who
require more regular surveillance. In addition, as most adenoma
patients face a lifetime of burdensome colonoscopies with its
associated bowel preparation and procedural risks, targeting
surveillance to high-risk patients would also likely increase
compliance with recommended follow-up colonoscopy intervals,
which is often poor; only 36% of patients comply with clinical
guideline recommended intervals for surveillance colonoscopy in
Australia (31). Moreover, with increasing incidence in CRC seen
in younger age groups (32, 33), especially those under eligibility
age thresholds for FOBT programs (34), and differential surveillance colonoscopy compliance based on patient insurance status
(35), risk stratification holds additional benefits for particular
patient groups.
The literature on risk stratification for CRC prevention
primarily incorporates factors such as family history and sociodemographics (age, sex, and socioeconomic status) with some
models also incorporating genetic variants associated with CRC
susceptibility (36). Where surveillance colonoscopy is considered, adenoma number, size, villosity, and dysplasia grade at the
most recent investigation are the more common determinants
for recommending future surveillance intervals, whereas other

Frontiers in Public Health | www.frontiersin.org

2

September 2017 | Volume 5 | Article 234

Preen et al.

Improving Precision of Colonoscopy Surveillance

determine CRC risk after a series of surveillance examinations,
stratified by risk parameters of the baseline adenomas (15). This
has also been highlighted as an important area in an Australian
gap analysis (44).

stratification models for informing timing of ongoing follow-up
colonoscopy for CRC is possible. Such work can also be tailored
to jurisdictional-specific settings and precedents exist for the
adaption of the MISCAN-Colon model to local settings, such as
the Australian-specific variant of MISCAN-Colon (50).

OPPORTUNITIES IN THE CURRENT DATA
ENVIRONMENT

CONCLUSION
Whole-population data linkage systems are uniquely placed to
allow robust longitudinal investigation to develop risk stratification models for CRC surveillance. Systems would require the
capacity to link data collections comprising demographic, cancer
registry, hospital inpatient, pathology, mortality, and genealogical
factors over multiple decades at the whole-of-population level.
The ability to link additional behavioral risk factor data (e.g.,
smoking, alcohol consumption, and dietary intake) from sources
such as large cohort studies would also add value. The linking
of such data collections would allow relevant risk factors to be
accounted for in risk stratification models, including the incorporation of complete colonoscopy history and adenoma burden over
time, which represents a potentially important modifying factor
for cancer risk but is currently not included in risk modeling for
recurrent adenoma of CRC.
In addition to providing greater precision with patient risk
profiling, estimates can be used in cost-effectiveness analyses
to determine optimal colonoscopy surveillance intervals for
patients at different levels of cancer risk. This could reduce costs
to the health system without a reduction in the number of CRCs
that surveillance colonoscopy prevents. Such information also
has capacity to support rational decisions concerning the best
strategy for repeat surveillance via colonoscopy for patients
at both low and high risk for CRC and reduce excessive delays
for surveillance colonoscopy, especially for high-risk patients.
Moreover, it creates an evidence-base for recommendations that
would be immediately implementable in clinical practice with
the potential to influence national colonoscopy surveillance
guidelines.

The emergence of whole-population data linkage systems in
many countries has afforded the opportunity to combine comprehensive data from a range of health service data collections
for large samples over decades. Such linkage systems provide a
powerful resource for conducting longitudinal research on large
or even entire populations and have benefits for minimizing, if
not overcoming, limitations due to sample size, selection bias,
response or recall bias, loss-to-follow-up, and ascertainment of
accurate health service exposure and outcome measures. The use
of such data has become commonplace in health research (45),
and linkage of whole-population non-consented service data for
research purposes is an accepted ethical approach (46).
Data from such linkage systems could also lay the foundation
for more robust risk stratification of populations, incorporating
a wide range of sociodemographic, clinical, and genetic factors
depending on the data available to be linked. Linkage systems,
such as the Western Australian Data Linkage System (47), use
widely accepted probabilistic-matching techniques and already
have capacity to link decades of cancer registry, inpatient, pathology, and mortality data, combined with the ability to genealogically link patients at the individual-level to derive familial history
of disease and “genetic” risk factors. Such data provide a unique
platform to investigate different risk stratification models for
CRC detection through colonoscopy surveillance. Moreover,
due to the extensive observation periods that can be investigated,
these systems provide the opportunity to incorporate data based
on findings over multiple surveillance colonoscopies, which
have been omitted from the literature to date but are likely
an important component for precision targeting of ongoing
surveillance windows. Additional linkage to National Bowel
Cancer Screening Program records and large cohort studies,
which may provide information on a range of health behaviors
not routinely captured in administrative data such as smoking,
alcohol consumption, diet, and physical activity would further
enhance the ability to precisely stratify CRC risk and tailor
appropriate follow-up intervals. The lack of such behavioral risk
factor information, rarely captured in administrative data, is a
potential limitation and arguably does not allow all risk factors
to be considered in risk stratification models. However, available
administrative data do allow targeting of factors most relevant to
guideline-based decision making in this area. Furthermore, the
approach proposed in this paper would still provide an advance
on existing risk-stratification models as a result of accounting for
the cumulative burden of prior colorectal adenoma which has
been omitted from risk stratification approaches to CRC screening and surveillance to date.
In addition, when combined with the availability of tools such
as MISCAN-Colon, a well-established microsimulation model for
CRC (48, 49), evaluation of the cost-effectiveness of different risk
Frontiers in Public Health | www.frontiersin.org
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